Story

Jazz Pharmaceuticals Stock Climbs on FDA Approval for Cancer Therapy Ziihera

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20261 min read
Jazz Pharmaceuticals Stock Climbs on FDA Approval for Cancer Therapy Ziihera
Text size
Background

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) gained 2.3% in Tuesday trading following the U.S. Food and Drug Administration's (FDA) approval of its new cancer therapy, Ziihera. The drug is now approved for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma (GEA).

Details of the Approval

The FDA greenlit two Ziihera-containing regimens for patients, regardless of their PD-L1 status. Ziihera is the first bispecific HER2-targeted antibody to be approved in combination with a PD-1 inhibitor and chemotherapy for this patient population.

This approval addresses a significant need, as approximately 20% of patients with gastroesophageal adenocarcinoma have HER2-positive disease. According to the source, more than 31,000 new cases of stomach cancer are diagnosed annually in the United States.

Clinical Trial Backing

Sample IUX Markets – In-articleAd

The regulatory decision was based on positive results from the Phase 3 HERIZON-GEA-01 trial. The study demonstrated that Ziihera-based combinations provided a significant clinical benefit compared to the standard of care, trastuzumab plus chemotherapy.

Key findings from the trial include:

  • A 35% reduction in the risk of disease progression or death.
  • An extension of median progression-free survival to 12.4 months, compared to 8.1 months for the control arm.
  • A 28% reduction in the risk of death in the overall HER2-positive population.
  • A median overall survival of 26.4 months, versus 19.2 months for the control arm.

Jazz Pharmaceuticals noted that the median overall survival figure is the longest reported in a Phase 3 trial for patients with HER2-positive advanced GEA. The company also reported that while diarrhea was the most common adverse reaction, it was generally manageable and resulted in few treatment discontinuations.

Read next

More on Stocks
Back to latest news

LATEST